Nasal continuous positive airway pressure (CPAP) and Nasal High Flow (NHF) therapy are two primary therapies for the treatment of respiratory distress in newborns. However, a considerable number of infants, who are initially treated with CPAP and NHF, will develop worsening respiratory failure and eventually require intubation for mechanical ventilation and the administration of surfactant. Infants who fail noninvasive respiratory therapy may suffer the consequences of delayed intubation, surfactant administration and other adverse outcomes. The most challenging decisions in the management of respiratory distress after birth is to decide when to move from a noninvasive respiratory support to invasive mechanical ventilation and give surfactant to decrease pulmonary damage and improve outcomes. There are no clinically adequate predictors of early CPAP failure at the time of admission to the neonatal intensive care unit. Many measurements have been investigated for their ability to predict CPAP failure in infants such as fraction of inspired oxygen (FiO2), partial pressure of oxygen (PaO2), PaO2/FiO2 and the stable micro bubble test as soon as possible after birth. Roca and colleagues first established the ROX index to predict the success of NHF therapy in adults with pneumonia. The ROX index combines three common measurements: FiO2, peripheral oxygen saturation (SpO2) and respiratory rate. Combining the ROX values with the change in the respiratory rate and FiO2 can indicate whether escalation is required. It was proposed that XY plot of the key components of ROX may show the direction of changes in vector form. The investigators hypothesized that the ROX index and ROX vector can be used for predicting the failure of CPAP and NHF in neonates.
The objective is to explore the usefulness of ROX index to predict treatment failure of NHF and CPAP therapies in neonates. The primary outcome is treatment failure within 72 h after start of the therapy with NHF or CPAP Treatment failure criteria is reached once an infant is receiving maximal therapy for their treatment (NHF 8 L/min) or CPAP 7 cm H2O plus at least one of: 1. Sustained increase in oxygen requirement ≥50% to maintain peripheral oxygen saturation (SpO2) 90%-94%. 2. Any infant requiring urgent intubation and the subsequent mechanical ventilation, as determined by the physician.
Study Type
OBSERVATIONAL
Enrollment
100
Newborns with respiratory distress treated with NHF.
Newborns with respiratory distress treated with CPAP.
Erebouni Medical Centre, NICU
Yerevan, Armenia
RECRUITINGRepublican Institute of Reproductive Health, NICU
Yerevan, Armenia
NOT_YET_RECRUITINGResearch Center of Maternal and Child Health Protection NICU
Yerevan, Armenia
NOT_YET_RECRUITINGNumber of participants requiring escalation of treatment
Treatment failure criteria is reached once an infant is receiving maximal therapy for their treatment (NHF 8 L/min) or CPAP 7 cm H2O plus at least one of: 1. Sustained increase in oxygen requirement above ≥50% to maintain peripheral oxygen saturation (SpO2) 90%-94%. 2. Any infant requiring urgent intubation and the subsequent mechanical ventilation, as determined by the physician.
Time frame: 72 hours
Number of participants with death
Death before discharge from the hospital
Time frame: Monitored for the entire stay in hospital, until discharge, up to 6 months
Number of participants with pneumothorax
Pneumothorax determined by chest radiograph
Time frame: Monitored for the entire stay in hospital, until discharge, up to 6 months
Number of participants with Necrotizing enterocolitis stage II-III
Necrotizing enterocolitis determined by abdominal radiograph
Time frame: Monitored for the entire stay in hospital, until discharge, up to 6 months
Number of participants with Intra-ventricular hemorrhage
Intra ventricular hemorrhage confirmed by head ultrasound
Time frame: Monitored for the entire stay in hospital, until discharge, up to 6 months
Number of participants with Bronchopulmonary dysplasia
Bronchopulmonary dysplasia
Time frame: through study completion, up to 6 months
Number of participants with Cystic Periventricular Leukomalacia
Cystic Periventricular Leukomalacia confirmed by ultrasound
Time frame: Monitored for the entire stay in hospital, until discharge, up to 6 months
Number of participants with PDA needed surgical treatment
Patent ductus arteriosus
Time frame: Monitored for the entire stay in hospital, until discharge, up to 6 months
Number of participants with ROP needing laser treatment
Retinopathy of prematurity needing laser treatment
Time frame: Monitored for the entire stay in hospital, until discharge, up to 6 months
Number of participants requiring blood transfusion
Blood transfusion
Time frame: Monitored for the entire stay in hospital, until discharge, up to 6 months
total number of days on O2 / noninvasive ventilation
total number of days on O2 / noninvasive ventilation
Time frame: Monitored for the entire stay in hospital, until discharge, up to 6 months
Total number days in the hospital
Total number days in the hospital
Time frame: Monitored for the entire stay in hospital, until discharge, up to 6 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.